BSE
GUFICBIO

GUFIC BIOSCIENCES LTD.

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

GUFIC BIOSCIENCES LTD. Stock Price

Vitals

Today's Low:
₹286.9
Today's High:
₹318.3
Open Price:
₹307
52W Low:
₹177.1
52W High:
₹263.05
Prev. Close:
₹296.45
Volume:
66239

Company Statistics

Market Cap.:
₹23.42 billion
Book Value:
35.923
Revenue TTM:
₹6.91 billion
Operating Margin TTM:
16.27%
Gross Profit TTM:
₹3.61 billion
Profit Margin:
11.54%
Return on Assets TTM:
10.16%
Return on Equity TTM:
25.84%

Company Profile

GUFIC BIOSCIENCES LTD. had its IPO on under the ticker symbol GUFICBIO.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. GUFIC BIOSCIENCES LTD. has a staff strength of 0 employees.

Stock update

Shares of GUFIC BIOSCIENCES LTD. opened at ₹307 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹286.9 - ₹318.3, and closed at ₹293.3.

This is a -1.06% slip from the previous day's closing price.

A total volume of 66,239 shares were traded at the close of the day’s session.

In the last one week, shares of GUFIC BIOSCIENCES LTD. have slipped by -8.01%.

GUFIC BIOSCIENCES LTD.'s Key Ratios

GUFIC BIOSCIENCES LTD. has a market cap of ₹23.42 billion, indicating a price to book ratio of 6.9111 and a price to sales ratio of 3.1702.

In the last 12-months GUFIC BIOSCIENCES LTD.’s revenue was ₹6.91 billion with a gross profit of ₹3.61 billion and an EBITDA of ₹1.35 billion. The EBITDA ratio measures GUFIC BIOSCIENCES LTD.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, GUFIC BIOSCIENCES LTD.’s operating margin was 16.27% while its return on assets stood at 10.16% with a return of equity of 25.84%.

In Q1, GUFIC BIOSCIENCES LTD.’s quarterly earnings growth was a negative -10.5% while revenue growth was a positive 6.7%.

GUFIC BIOSCIENCES LTD.’s PE and PEG Ratio

Forward PE
0
Trailing PE
28.9628
PEG

Its diluted EPS in the last 12-months stands at ₹8.34 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into GUFIC BIOSCIENCES LTD.’s profitability.

GUFIC BIOSCIENCES LTD. stock is trading at a EV to sales ratio of 3.3769 and a EV to EBITDA ratio of 17.3266. Its price to sales ratio in the trailing 12-months stood at 3.1702.

GUFIC BIOSCIENCES LTD. stock pays annual dividends of ₹0.1 per share, indicating a yield of 0.04% and a payout ratio of 3.15%.

Balance sheet and cash flow metrics

Total Assets
₹8.61 billion
Total Liabilities
₹2.88 billion
Operating Cash Flow
₹0
Capital Expenditure
₹0
Dividend Payout Ratio
3.15%

GUFIC BIOSCIENCES LTD. ended 2024 with ₹8.61 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹8.61 billion while shareholder equity stood at ₹3.48 billion.

GUFIC BIOSCIENCES LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹2.88 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹286.02 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹1.91 billion.

GUFIC BIOSCIENCES LTD.’s total current assets stands at ₹4.64 billion while long-term investments were ₹0 and short-term investments were ₹180.85 million. Its net receivables were ₹2.05 billion compared to accounts payable of ₹1.30 billion and inventory worth ₹1.83 billion.

In 2024, GUFIC BIOSCIENCES LTD.'s operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, GUFIC BIOSCIENCES LTD. paid ₹0.03 in dividends in 2024.

Other key metrics

Current Trading Price
₹293.3
52-Week High
₹263.05
52-Week Low
₹177.1
Analyst Target Price

GUFIC BIOSCIENCES LTD. stock is currently trading at ₹293.3 per share. It touched a 52-week high of ₹263.05 and a 52-week low of ₹263.05. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹266.04 and 200-day moving average was ₹224.72 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 7811.5% of the company’s stock are held by insiders while 108.3% are held by institutions.

Frequently Asked Questions About GUFIC BIOSCIENCES LTD.

The stock symbol (also called stock or share ticker) of GUFIC BIOSCIENCES LTD. is GUFICBIO

The IPO of GUFIC BIOSCIENCES LTD. took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
₹2
0.14
+7.53%
Moog Inc (MOG-A)
₹112.43
-2.23
-1.94%
₹0.03
0
+20%
Rossell India Limited (ROSSELLIND)
₹481.55
-27.9
-5.48%
₹0.12
0.01
+5.31%
₹2.54
-0.19
-6.92%
₹23.34
0.15
+0.65%
Coursera Inc (COUR)
₹18.39
0.16
+0.88%
₹84.79
-4.31
-4.84%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.

Address